Posted January 21, 2009
Iconic Therapeutics
Georgia-based Iconic Therapeutics raises $2.57M
Post a comment
Print this storyE-mail story
Share
Iconic Therapeutics
Site Search
ATLANTA, Ga. —
Iconic Therapeutics, a startup focused on a new means of combating cancer and eye disease, has closed on $2.57 million in third-round financing.
VentureWire reported the closing Tuesday. Iconic is seeking to raise $4.2 million.
Icon is in pre-clinical development of technology discovered at Yale University that uses molecules called icon to kill tumors. The icon molecules kill tumors by destroying the blood vessels that feed them.
The company also is combating wet macular degeneration, an eye disease that destroys the vision in older Americans. There are two forms of macular degeneration that destroys the retina – wet, which affects about 10 percent of victims, and dry.
Icon licensed the technology from Yale.
Featured
Hot Off The Wire
- Hot Off the Wire – Apple charges $107 for iPad batteries; Amazon drops Colorado affiliates like it did in N.C.; Facebook expands in India
- Hot Off the Wire – $5M bonus for Apple exec; Disney to shut studio, cut 450 jobs; Motorola co-CEO’s pay $3.77M; Adobe CEO pay plunges 68%
- Hot Off the Wire – No ‘xxx’ domains yet, Net agency says; Analyst ups Google stock value; Vin Gupta leaves InfoGroup board
Venture & Innovation
- Venture Briefs – Georgia software firm raises $110M; Few VCs on billionaire list; Entrepreneur outlines strategy for sales leads
- CED picks nine more companies to present at venture conference
- Venture Briefs – A top VC uses blog to generate wider dealfow; CA pays $350M for cloud computing firm; Battery closes on $750M fund
E-mail Preferences
